Thomas Borcholte

Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA.

NextGen Group Plc provides protein biomarker testing services for pharmaceutical and biotech companies. Its services include biomarker discover, assay development and testing laboratory. The company's biomarker assay used to test pre-clinical and clinical samples for drug efficacy and safety, and for the development of personalized treatment for patients. Its biomarker services include protein identification, characterization, quantitation and proteome mapping. The company was founded on September 7, 2005 and is headquartered in London, the United Kingdom.

Topotarget A/S is a biotechnology company that is engaged in the development and commercialization of novel drugs for the treatment of cancer. Its product belinostat is a novel histone deacetylase inhibitor which is used for cancer patients. The company was founded by Peter Buhl Jensen and Maxwell Sehested in 2000 and is headquartered in Copenhagen, Denmark.

Part of GSK Plc, Wellcome Plc is a British company that specializes in the discovery, development, manufacture, and sale of human healthcare products. The company is based in Greenford, UK.

TopoTarget UK Ltd. engages in the discovery and development of drugs and therapies to treat cancer. It develops anti-cancer drugs for molecular mechanisms associated with the cell cycle, chromatin control and DNA damage. The company was founded in 2002 and is headquartered in Oxford, the United Kingdom.

NextGen Sciences Ltd. provides technologies and reagents for molecular biology and protein research. Its advanced products automate and simplify complex research techniques, saving time and resources, improving results, and accelerating discovery. The company was founded on January 28, 2000 by Kevin Auton and David Wigley and is headquartered in Huntingdon, the United Kingdom.

Part of Nuclea Biotechnologies, Inc., Wilex, Inc. develops medical diagnostic tests. The company is based in Cambridge, MA. The CEOs of the company are Thomas Borcholte, Olaf G. Wilhelm. Wilex was acquired by Nuclea Biotechnologies, Inc. from Heidelberg Pharma AG on September 06, 2013.